Vaccines targeting serogroup B meningococci

Affiliations

Comment

Muhamed-Kheir Taha et al. Lancet Infect Dis. 2012 Aug.

. 2012 Aug;12(8):578-9.

doi: 10.1016/S1473-3099(12)70093-2. Epub 2012 May 7.

¹ Institut Pasteur, Unit of Invasive Bacterial Infections & National Reference Center for Meningococci, 75724 Paris, Cedex 15, France. mktaha@pasteur.fr

No abstract available

Comment on

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators. Richmond PC, et al. Lancet Infect Dis. 2012 Aug;12(8):597-607. doi: 10.1016/S1473-3099(12)70087-7. Epub 2012 May 7. Lancet Infect Dis. 2012. PMID: 22569484 Clinical Trial.